OCON Therapeutics announces FDA acceptance of IND Application for its flagship product IUB® Ballerine® and distribution agreements for Canada and Mexico boosting sales by $9.3 million
June 22, 2022
OCON Healthcare, a women’s health company which develops, manufactures and commercializes innovative 3D intrauterine drug delivery technology based on its patented IUBTM (Intra-Uterine Ball) platform, announced that it has signed exclusive and binding distribution agreements with Global contraception giant, DKT, for an additional ten territories in the Mexico and northern LATAM region, as well as women’s health specialist, Searchlight Pharma, for the Canadian market, totaling $9.3 million. The continued growth of the IUB Ballerine® is followed by the announcement that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for the non-hormonal IUB Ballerine®, its flagship long acting reversible contraceptive (LARC). The active IND allows initiation of the company’s U.S. pivotal study planned to initiate in 2023.
OCON Therapeutics has signed an exclusive licensing agreement with BioGenuine to market its products in China and Southeast Asian countries
June 21, 2022
OCON Healthcare, the Israeli FEMTECH company, which develops, manufactures and markets a unique and innovative platform for the delivery of drugs to the uterus, reports that it has signed an exclusive licensing agreement with BioGenuine, a Chinese pharma company in the field of Women’s Health, which will begin marketing its products exclusively in China and Southeast Asia. It is also stipulated that the companies will work for the joint development and commercialization of new products in the field of women’s health based on OCON’s spherical platform combined with innovative drugs.
OCON Therapeutics Awarded as Technology Pioneer by the World Economic Forum
May 11, 2022
The World Economic Forum announced its selection of the 100 most promising Technology Pioneers of 2022 – companies that are tackling issues from healthcare to sustainability and climate change and more.
OCON Healthcare, a Women’s Health revolution created the world’s first and only three-dimensional (3D) spherical intrauterine drug-delivery platform technology addressing a myriad of women’s health issues through the uterus (such as contraception, heavy bleeding, endometriosis, fibroids, menopause and more), avoiding systemic side effects from taking oral formulations, made it to the selection for its contributions in the field of Healthcare and impact in women’s health.
OCON’s Pioneering IUB® Ballerine® Femtech Applauded by Frost & Sullivan
April 23, 2021
Frost & Sullivan recognizes OCON Healthcare (OCON) with the 2021 Global Enabling Technology Leadership Award for creating the world’s first and only 3D spherical copper IUD, the Intra Uterine Ball (IUB)™ Ballerine®.
IUB, OCON and the OCON and IUB logos are trademarks of OCON Medical Ltd. Ballerine and Sphera are registered trademarks of OCON Medical Ltd. OCON products are not yet approved for sale in the United States. IUB Ballerine MAXI: CE mark pending. Copyright OCON Medical Ltd., d/b/a OCON Therapeutics.